Opus Medical Therapies, LLC — SEC Form D Filing
Opus Medical Therapies, LLC filed an SEC Form D on September 22, 2026, reporting $485K raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- September 22, 2026
- Amount reported
- $485K
- Round stage
- Seed stage, as a sub-half-million-dollar equity raise represents an early-stage capital injection typical of initial formulation and preclinical validation phases.
- Industry
- Biotechnology
- Website
- https://opusmedicaltherapies.com
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: GEORGIA
Problem
Patients suffering from chronic degenerative conditions lack targeted, biocompatible therapies that can actively repair damaged tissue without triggering severe immune responses.
Solution
Opus Medical Therapies develops advanced regenerative biomaterials and targeted therapeutic agents designed to restore damaged tissue function.
Why now
Recent breakthroughs in biocompatible materials and precision delivery systems now enable the localized administration of regenerative therapies directly to diseased tissues.
Source: SEC EDGAR Form D filing